Cargando…

Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Adjuvant chemotherapy (ACT) is routinely the recommended treatment for patients with advanced non-small cell lung cancer (NSCLC) but remains a controversial option in stage IB patients. We therefore pooled the current evidence to determine the prognostic impact of ACT in stage IB NSCLC p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaofan, Chen, Donglai, Wen, Junmiao, Mao, Yiming, Zhu, Xuejuan, Fan, Min, Chen, Yongbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506786/ https://www.ncbi.nlm.nih.gov/pubmed/34733982 http://dx.doi.org/10.21037/atm-21-4001

Ejemplares similares

Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study
por: Chen, Donglai, et al.
Publicado: (2020)

Overall Survival Analyses following Adjuvant Chemotherapy or Nonadjuvant Chemotherapy in Patients with Stage IB Non-Small-Cell Lung Cancer
por: Tu, Zegui, et al.
Publicado: (2021)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database
por: Wen, Junmiao, et al.
Publicado: (2019)

Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB Non-Small Cell Lung Cancer
por: Li, Da-Peng, et al.
Publicado: (2015)

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023)

Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2022)

Numbers and Stations: Impact of Examined Lymph Node on Precise Staging and Survival of Radiologically Pure-Solid NSCLC: A Multi-Institutional Study
por: Chen, Donglai, et al.
Publicado: (2020)

Role of adjuvant treatment in stage IB non-small cell lung carcinoma
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer
por: Xu, Yangyang, et al.
Publicado: (2022)

A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
por: Song, Xue, et al.
Publicado: (2023)

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: He, Jiaxi, et al.
Publicado: (2015)

Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
por: Park, Seong Yong, et al.
Publicado: (2013)

Efficacy and Benefit of Postoperative Chemotherapy in Micropapillray or Solid Predominant Pattern in Stage IB Lung Adenocarcinoma: A Systematic Review and Meta-Analysis
por: Xu, Congcong, et al.
Publicado: (2021)

Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer
por: Matsuo, Koji, et al.
Publicado: (2017)

Should adjuvant treatment be offered to patients with stage IB non-small cell lung cancer?
por: Passiglia, Francesco, et al.
Publicado: (2023)

Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors
por: Choi, Juwhan, et al.
Publicado: (2022)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
por: Cao, Shuhui, et al.
Publicado: (2018)

Log odds of positive lymph nodes is a robust predictor of survival and benefits from postoperative radiotherapy in stage IIIA‐N2 resected non‐small cell lung cancer
por: Jin, Xing, et al.
Publicado: (2022)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma
por: Xu, Xuejun, et al.
Publicado: (2023)

LTF Induces Radioresistance by Promoting Autophagy and Forms an AMPK/SP2/NEAT1/miR-214-5p Feedback Loop in Lung Squamous Cell Carcinoma
por: Wen, Junmiao, et al.
Publicado: (2023)

Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses
por: Chen, Donglai, et al.
Publicado: (2021)

Nomograms for predicting survival outcomes in patients with primary tracheal tumors: a large population-based analysis
por: Wen, Junmiao, et al.
Publicado: (2018)

A novel nomogram for identifying candidates for adjuvant chemotherapy in patients with stage IB gastric adenocarcinoma
por: Xie, Yangyang, et al.
Publicado: (2023)

Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer
por: Chen, Yuan-Yuan, et al.
Publicado: (2015)

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences
por: Xu, Fei, et al.
Publicado: (2022)

Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy
por: Singh, Sareena, et al.
Publicado: (2015)

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011)

Does the lymph node yield affect survival in patients with esophageal cancer receiving neoadjuvant therapy plus esophagectomy? A systematic review and updated meta-analysis
por: Chen, Donglai, et al.
Publicado: (2020)

Elderly patients with stage II gastric cancer do not benefit from adjuvant chemotherapy
por: Guo, Jianping, et al.
Publicado: (2023)

Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB–IIA cervical cancer patients
por: Lee, Kwang-Beom, et al.
Publicado: (2018)

Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis
por: Zhou, Ke, et al.
Publicado: (2022)

Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer
por: Lei, Tao, et al.
Publicado: (2016)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis
por: Mao, Yiming, et al.
Publicado: (2018)

Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer
por: Yan, Shi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_nrup7vj4nfd7khk0icv2u0qe3m